10-Q: Amylyx Pivots Post-RELYVRIO, Advances New Pipeline

Amylyx Pharmaceuticals reports significant losses following the discontinuation of its lead commercial product, RELYVRIO, while advancing new investigational therapies with positive early clinical data and securing fresh capital.

Summary

• Amylyx Pharmaceuticals, Inc. reported a net loss of $41.4 million for the three months ended June 30, 2025, an improvement from a $72.7 million net loss in the same period of 2024.
• For the six months ended June 30, 2025, the net loss was $77.4 million, significantly lower than the $191.5 million loss in the prior year period.
• Product revenue was $0 for both the three and six months ended June 30, 2025, compared to $(1.0) million and $87.6 million, respectively, in the prior year, due to the voluntary discontinuation of RELYVRIO/ALBRIOZA.
• Research and development expenses increased by 17% to $27.2 million for the three months ended June 30, 2025, driven by the pivotal Phase 3 LUCIDITY trial for avexitide in PBH and increased spending on AMX0035 for PSP.
• Selling, general and administrative expenses decreased by 28% to $15.6 million for the three months ended June 30, 2025, primarily due to a 70% workforce reduction and decreased commercial sales and marketing activity following the RELYVRIO/ALBRIOZA discontinuation.
• The company completed an underwritten public offering in January 2025, raising approximately $65.5 million in net proceeds.
• Cash, cash equivalents, and marketable securities totaled $180.8 million as of June 30, 2025, which is expected to fund operations through 2026.
• The Phase 3 LUCIDITY clinical trial for avexitide in post-bariatric hypoglycemia (PBH) dosed its first participant in April 2025, with topline data anticipated in the first half of 2026.
• Positive long-term data through Week 48 from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome was announced in May 2025, showing sustained improvement in pancreatic beta cell function and glycemic control.
• Enrollment in the Phase 2b portion of the ORION trial for AMX0035 in progressive supranuclear palsy (PSP) was completed in January 2025, with interim analysis data expected in Q3 2025.
• The Phase 1 LUMINA clinical trial for AMX0114 in amyotrophic lateral sclerosis (ALS) dosed its first participant in April 2025, following the lifting of a clinical hold in January 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the company has secured funding and is advancing new pipeline candidates with some positive early data, the complete discontinuation of its only commercial product (RELYVRIO/ALBRIOZA) due to failed trials represents a significant setback and loss of revenue. The company remains unprofitable with a large accumulated deficit and faces substantial future funding needs and ongoing litigation risks. The reduction in losses is largely due to cost-cutting measures rather than new revenue generation.

Positives

• Net loss significantly decreased by 43% for the three months and 60% for the six months ended June 30, 2025, compared to the prior year periods, primarily due to reduced operating expenses from restructuring and product discontinuation.
• Successful completion of a public offering in January 2025 raised approximately $65.5 million, strengthening the cash position.
• Cash, cash equivalents, and marketable securities of $180.8 million as of June 30, 2025, are projected to fund operations through 2026.
• Avexitide, the lead investigational asset, has received Breakthrough Therapy Designation for both PBH and congenital hyperinsulinism (HI), Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for hyperinsulinemic hypoglycemia.
• The pivotal Phase 3 LUCIDITY clinical trial for avexitide in PBH has commenced, with recruitment expected to complete in 2025 and topline data in H1 2026.
• Positive long-term data from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome demonstrated sustained improvement in pancreatic beta cell function, glycemic control, and visual acuity, with all adverse events being mild or moderate.
• Enrollment for the Phase 2b portion of the ORION trial for AMX0035 in PSP was completed ahead of schedule in January 2025.
• AMX0114 for ALS received Fast Track designation, and its Phase 1 LUMINA trial has begun, with early cohort data expected in 2025, following the lifting of a prior clinical hold.

Negatives

• Product revenue for the three and six months ended June 30, 2025, was $0, a significant decline from $87.6 million in the prior year period, due to the voluntary discontinuation of RELYVRIO/ALBRIOZA.
• The company continues to incur significant operating losses, with an accumulated deficit of $684.0 million as of June 30, 2025.
• The discontinuation of RELYVRIO/ALBRIOZA was based on failed topline results from the Phase 3 PHOENIX trial, indicating a significant setback for the company's prior lead commercial product.
• Research and development expenses are expected to increase in the near term due to ongoing clinical development activities for new product candidates.
• The company will need substantial additional funding beyond 2026 to continue its development efforts and fund ongoing operating expenses, with no assurance of obtaining financing on acceptable terms.
• The company is subject to multiple ongoing legal proceedings (class action and derivative lawsuits) alleging false and misleading statements related to RELYVRIO, with an unknown financial impact.

Risks

• Cessation of marketing and selling the previous commercial product (RELYVRIO/ALBRIOZA) means no continued revenue from this product, leading to expected significant losses for the foreseeable future.
• Profitability is contingent on successfully commercializing current or future product candidates, which is highly speculative and uncertain.
• Quarterly and annual operating results may fluctuate, potentially causing stock price decline and negatively impacting financing ability.
• Substantial additional funding will be required; inability to obtain it could force delays, reductions, or elimination of product discovery, development, or commercialization efforts.
• Heavy dependence on the success of avexitide and AMX0035; failure or significant delays in late-stage trials or regulatory approvals would materially harm the business.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with potential for delays, denials, or withdrawal of approval.
• Limited experience in endocrine and metabolic drug development (new focus area with avexitide) presents additional challenges.
• Reliance on third parties for clinical trials and manufacturing increases risks of unsatisfactory performance, delays, or supply issues.
• Markets for avexitide and AMX0035 may be smaller than expected, impacting potential revenue.
• Inability to expand sales, marketing, manufacturing, and distribution capabilities or secure third-party agreements would prevent additional product revenue generation.
• Even if approved, products may fail to gain or maintain sufficient market acceptance by physicians, patients, and third-party payors.
• Inadequate intellectual property protection (patents, trade secrets) could allow competitors to erode competitive advantage.
• Operating in a period of economic uncertainty and capital markets disruption (geopolitical instability, inflation, interest rates, tariffs) could adversely affect business.
• Dependence on key executive officers and principal consultants; loss of their services would materially harm the business.
• Limited number of employees to manage and operate the business following a 70% workforce reduction.
• Strategic transactions, including acquisitions, may not produce anticipated benefits and carry integration risks.
• Stock price volatility is expected due to various factors, including clinical trial results and regulatory decisions.
• No cash dividends are anticipated in the foreseeable future, requiring stockholders to rely on capital appreciation.
• Concentration of common stock ownership among existing executive officers, directors, and principal stockholders may limit new investors' influence.
• Delaware law and company bylaws could make mergers, tender offers, or proxy contests difficult, potentially depressing stock price.
• Failure to maintain proper and effective internal control over financial reporting could impair financial statements and harm investor confidence.
• Subject to ongoing securities class action litigation and potential future litigation, which could be costly and divert resources.
• Ability to use net operating losses and research and development credits to offset future taxable income may be subject to limitations due to ownership changes.
• Failure to meet Nasdaq's continued listing requirements could result in delisting of common stock.
• Negative evaluations by securities analysts could cause stock price decline.
• Cyber-attacks, data breaches, or other failures in IT systems could result in information theft, business disruption, and reputational damage.
• Compliance with global privacy and data security requirements could result in additional costs and liabilities.
• Artificial intelligence presents risks and challenges, including security risks to confidential information and potential reputational harm.

Future Outlook

The company expects to continue generating operating losses for the foreseeable future and will not return to profitability unless and until it successfully commercializes any of its current or future product candidates. Research and development expenses are anticipated to increase in connection with planned clinical development activities. Existing cash, cash equivalents, and marketable securities are expected to fund operating expenses and capital expenditure requirements through 2026. Substantial additional funding will be required beyond this period through equity offerings, debt financings, collaborations, or licensing arrangements to fund ongoing research and development and operating expenses. Topline data for the avexitide Phase 3 LUCIDITY trial is anticipated in the first half of 2026, with commercial launch expected in 2027 if approved. Efficacy and safety data from an unblinded interim analysis of the AMX0035 ORION trial (PSP) is anticipated in Q3 2025 to inform a go/no-go decision for the Phase 3 portion. Early cohort data from the AMX0114 LUMINA trial (ALS) are expected in 2025.

Management Comments

• We are a clinical-stage pharmaceutical company with a mission to develop novel therapies for communities with high unmet medical needs.
• We are advancing a pipeline in which we have matched investigational therapies with diseases where we believe they can make the greatest impact, based on well-defined mechanistic rationale, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality.
• We expect that our research and development expenses will continue to increase in connection with our planned clinical development activities in the near term and in the future.
• We expect that general and administrative expenses will increase in future periods as we advance our clinical pipeline.
• We believe our existing cash, cash equivalents and marketable securities as of June 30, 2025 will be sufficient to meet our anticipated operating and capital expenditure requirements through 2026.

Industry Context

The biotechnology industry, particularly in neurodegenerative diseases, has historically faced significant challenges with limited success in product development. Amylyx's pivot from its failed ALS drug (RELYVRIO/ALBRIOZA) to focus on new pipeline candidates like avexitide for post-bariatric hypoglycemia (an endocrine condition) and AMX0035 for Wolfram syndrome and PSP (neurodegenerative diseases) reflects a strategic re-prioritization common in the volatile biopharma sector. The company is pursuing orphan drug and breakthrough therapy designations, which are critical for rare disease markets, offering potential market exclusivity and expedited review. The ongoing legal challenges related to prior commercialization efforts highlight the inherent risks in drug commercialization and regulatory compliance within the industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for benchmarking against industry standards. The analysis is focused on the company's internal performance and pipeline progression.

Management Changes

Corporate Governance

Legal Proceedings

• A putative class action lawsuit, Shih v. Amylyx Pharmaceuticals, Inc., et al., was filed on February 9, 2024, alleging materially false and misleading statements related to the commercial results and prospects for RELYVRIO. A motion to dismiss is pending.
• A derivative complaint, Jones v. Cohen, et al., was filed on October 2, 2024, against certain current and former director and officer defendants, mirroring the Shih Complaint's allegations and including claims for breach of fiduciary duty, insider trading, and unjust enrichment. This action is currently stayed.
• A second derivative complaint, Hassine v. Cohen, et al., was filed on July 2, 2025, with substantive allegations mirroring the Shih Complaint and including additional claims. This complaint has been consolidated with the Jones Derivative Complaint and is also stayed.
• The company intends to vigorously defend against these complaints, and an estimate of their impact cannot be made at this time.

Stakeholder Impact

• **Shareholders:** Experience significant dilution from the January 2025 public offering and face potential future dilution from additional capital raises. Stock price volatility is expected due to clinical trial outcomes and financial performance. No cash dividends are anticipated.
• **Employees:** Experienced a 70% workforce reduction as part of the Restructuring Plan in April 2024, impacting job security and morale. Remaining employees are critical for advancing the pipeline.
• **Patients:** The discontinuation of RELYVRIO/ALBRIOZA means a previously available treatment for ALS is no longer on the market. New investigational therapies (avexitide, AMX0035, AMX0114) are in development for high unmet medical needs, offering potential future treatment options.
• **Creditors/Suppliers:** The company's financial stability and ability to meet future obligations depend on successful pipeline development and securing additional funding. Negotiations with third-party manufacturers are ongoing following the RELYVRIO/ALBRIOZA discontinuation.
• **Regulatory Authorities:** The company is actively engaged with the FDA and other regulatory bodies for various designations (Breakthrough Therapy, Orphan Drug, Fast Track) and approvals for its new product candidates, indicating ongoing regulatory scrutiny and compliance efforts.

Next Steps

• Complete recruitment for the Phase 3 LUCIDITY clinical trial for avexitide in PBH in 2025.
• Anticipate topline data from the Phase 3 LUCIDITY trial in the first half of 2026.
• Anticipate efficacy and safety data from an unblinded interim analysis of the Phase 2b portion of the ORION trial (AMX0035 for PSP) in Q3 2025 to inform a go/no-go decision for the Phase 3 portion.
• Expect early cohort data from the Phase 1 LUMINA clinical trial (AMX0114 for ALS) in 2025.
• Engage in discussions with the broader congenital HI community to develop a path forward for avexitide in that indication.
• Identify a lead development candidate for IND-enabling studies as part of the collaboration with Gubra A/S for a novel long-acting GLP-1 receptor antagonist.
• Inform the design of a Phase 3 trial of AMX0035 in Wolfram syndrome based on Phase 2 HELIOS data and discussions with the FDA.
• Continue to open U.S. sites for screening, enrollment, and dosing for the LUMINA trial (AMX0114 for ALS).
• Seek additional funding through equity offerings, debt financings, collaborations, strategic alliances, and/or licensing arrangements to fund future operations beyond 2026.
• Defend against ongoing class action and derivative lawsuits vigorously.

Key Dates

Recommendation

The company is in a transitional phase, having discontinued its only commercial product due to failed trials, which is a significant negative. However, it has successfully raised capital to extend its cash runway through 2026 and is actively advancing a new pipeline with promising early-stage clinical data for multiple rare diseases. The substantial accumulated deficit and the need for significant future funding present considerable risks. The ongoing legal proceedings add further uncertainty. Given the high-risk, high-reward nature of clinical-stage biopharmaceutical development, coupled with the recent strategic pivot and cash infusion, a 'hold' recommendation is appropriate. Investors should monitor the upcoming clinical trial data readouts (AMX0035 ORION interim analysis in Q3 2025, AMX0114 early cohort data in 2025, avexitide LUCIDITY topline data in H1 2026) and the company's ability to secure additional financing, as these will be critical determinants of future value.

Keywords

Biotechnology, Pharmaceuticals, Neurodegenerative Diseases, Endocrine Conditions, Post-Bariatric Hypoglycemia, Wolfram Syndrome, Progressive Supranuclear Palsy, Amyotrophic Lateral Sclerosis, Avexitide, AMX0035, AMX0114, Clinical Trials, Drug Development, Orphan Drug, Breakthrough Therapy, Fast Track Designation, SEC Filing, 10-Q, Financial Results, Biopharma